1. Bron LP, Traynor SJ, McNeil EB, O'Brien CJ. Primary and metastatic cancer of the parotid: comparison of clinical behavior in 232 cases. Laryngoscope. 2003;113:1070-5.

https://doi.org/10.1097/00005537-200306000-00029

PMid:12782825 

2. Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, Licitra L. F, et al. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?. Oral Oncol. 2017;66:58-63.

https://doi.org/10.1016/j.oraloncology.2016.12.016

PMid:28249649 

3. Devi KS, Anandasabapathy N. The origin of DCs and capacity for immunologic tolerance in central and peripheral tissues. Semin Immunopathol. 2017;39:137-52.

https://doi.org/10.1007/s00281-016-0602-0

PMid:27888331 PMCid:PMC5296242

4. Tang M, Diao J, Cattral MS. Molecular mechanisms involved in dendritic cell dysfunction in cancer. Cell Mol Life Sci. 2017;74:761-76.

https://doi.org/10.1007/s00018-016-2317-8

PMid:27491428 

5. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer. 2001;91:2136-47.

https://doi.org/10.1002/1097-0142(20010601)91:11<2136::AID-CNCR1242>3.0.CO;2-Q

PMid:11391595 

6. Dultra FK, Barros AC, Schaer-Barbosa H, Figueiredo AL, Gurgel CA, Ramos EA, et al. Immunohistochemical assessment of CD1a-positive Langerhans cells and their relationship with E-cadherin in minor salivary gland tumors. J Oral Pathol Med. 2012;41:47-53.

https://doi.org/10.1111/j.1600-0714.2011.01052.x

PMid:21627694 

7. Jardim JF, Gondak R, Galvis MM, Pinto CAL, Kowalski LP. A decreased peritumoral CD1a+ cell number predicts a worse prognosis in oral squamous cell carcinoma. Histopathology. 2018;72:905-13.

https://doi.org/10.1111/his.13415

PMid:29023924 

8. Velicković LJ, Dimov I, Petrović D, Stojnev S, Dacić S, Velicković S, et al. Stromal reaction and prognosis in acinic cell carcinoma of the salivary gland. Vojnosanit Pregl. 2013;70(12):1155-8.

https://doi.org/10.2298/VSP1312155J

PMid:24450262 

9. Skálová A, Hyrcza MD, Leivo I. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands. Head Neck Pathol. 2022;16:40-53.

https://doi.org/10.1007/s12105-022-01420-1

PMid:35312980 PMCid:PMC9018948

10. Peng X, He Y, Huang J, Tao Y, Liu S. Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy. Front Immunol. 2021;12:613492.

https://doi.org/10.3389/fimmu.2021.613492

PMid:33732237 PMCid:PMC7959811

11. Auclair PL. Tumor-associated lymphoid proliferation in the parotid gland. A potential diagnostic pitfall. Oral Surg Oral Med Oral Pathol. 1994;77:19-26.

https://doi.org/10.1016/S0030-4220(06)80102-7

PMid:8108090 

12. Harada K, Ferdous T, Ueyama Y. PD-L1 expression in malignant salivary gland tumors. BMC Cancer. 2018;18:156.

https://doi.org/10.1186/s12885-018-4069-3

PMid:29409471 PMCid:PMC5801834

13. Baleeiro RB, Bergami-Santos PC, Tomiyoshi MY, Gross JL, Haddad F, Pinto CA, et al. Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it? Cancer Immunol Immunother. 2007;57:265-70.

https://doi.org/10.1007/s00262-007-0344-x

PMid:17628801 

14. Ruiz-Cabello F, Garrido F. HLA and cancer: from research to clinical impact. Immunol Today. 1998;19:539-42.

https://doi.org/10.1016/S0167-5699(98)01349-8

PMid:9864942 

15. Lei WY, Hsiung SC, Wen SH, Hsieh CH, Chen CL, Wallace CG, et al. Total HLA Class I Antigen Loss with the Downregulation of Antigen-Processing Machinery Components in Two Newly Established Sarcomatoid Hepatocellular Carcinoma Cell Lines. J Immunol Res. 2018;2018:1-12.

https://doi.org/10.1155/2018/8363265

PMid:30648121 PMCid:PMC6311956

16. Mariano FV, Costa AF, Gondak RO, Martins AS, Del Negro A, Tincani ÁJ, et al. Cellular Proliferation Index between Carcinoma Ex-Pleomorphic Adenoma and Pleomorphic Adenoma. Braz Dent J. 2015;26:416-21.

https://doi.org/10.1590/0103-6440201300369

PMid:26312983 

17. Faur AC, Sas I, Motoc AG, Cornianu M, Zamfir CL, Lazăr DC, et al. Ki-67 and p53 immunostaining assessment of proliferative activity in salivary tumors. Rom J Morphol Embryol. 2015;56:1429-39.

PMid:26743291

18. Bjørndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, et al. Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol. 2011;47:677-82.

https://doi.org/10.1016/j.oraloncology.2011.04.020

PMid:21612974 

19. Carlinfante G, Lazzaretti M, Ferrari S, Bianchi B, Crafa P. P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up. Pathol Res Pract. 2005;200:791-9.

https://doi.org/10.1016/j.prp.2004.08.008

PMid:15792122 

20. Larsen SR, Bjørndal K, Godballe C, Krogdahl A. Prognostic significance of Ki-67 in salivary gland carcinomas. J Oral Pathol Med. 2012;41:598-602.

https://doi.org/10.1111/j.1600-0714.2012.01148.x

PMid:22530699 

21. Vacchi-Suzzi M, Bocciolini C, Bertarelli C, Dall'Olio D. Ki-67 proliferation rate as a prognostic marker in major salivary gland carcinomas. Ann Otol Rhinol Laryngol. 2010;119:677-83.

https://doi.org/10.1177/000348941011901006

PMid:21049853 

22. Jiang YH, Cheng B, Ge MH, Zhang G. The prognostic significance of p63 and Ki-67 expression in myoepithelial carcinoma. Head Neck Oncol. 2012;4:9.

https://doi.org/10.1186/1758-3284-4-9

PMid:22452794 PMCid:PMC3331847

23. Díaz KP, Gondak R, Martins LL, de Almeida OP, León JE, Mariano FV, et al. Fatty acid synthase and Ki-67 immunoexpression can be useful for the identification of malignant component in carcinoma ex-pleomorphic adenoma. J Oral Pathol Med. 2019;48:232-8.

https://doi.org/10.1111/jop.12820

PMid:30597641 

24. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267-84.

https://doi.org/10.1101/gad.314617.118

PMid:30275043 PMCid:PMC6169832

25. Mosconi C, de Arruda JAA, de Farias ACR, Oliveira GAQ, de Paula HM, Fonseca FP, et al. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncol. 2019;88:95-101.

https://doi.org/10.1016/j.oraloncology.2018.11.028

PMid:30616805 

26. Lavareze L, Scarini JF, de Lima-Souza RA, Emerick C, Sales de Sá R, Aquino IG, et al. Salivary gland cancer in the setting of tumor microenvironment: Translational routes for therapy. Crit Rev Oncol Hematol. 2022;171:103605.

https://doi.org/10.1016/j.critrevonc.2022.103605

PMid:35077805 

27. Egal ESA, Scarini JF, de Lima-Souza RA, Lavareze L, Fernandes PM, Emerick C, et al. Tumor microenvironment in salivary gland carcinomas: An orchestrated state of chaos. Oral Oncol. 2022;127:105777.

https://doi.org/10.1016/j.oraloncology.2022.105777

PMid:35189584